Antares Pharma to Present at the Jefferies London Healthcare Conference
10 nov. 2021 08h30 HE
|
Antares Pharma, Inc.
EWING, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief...
Antares Pharma Reports Third Quarter 2021 Financial and Operating Results
04 nov. 2021 07h00 HE
|
Antares Pharma, Inc.
Increased Revenue 20% Year-Over-Year to $48.2 Million Net Income of $5.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share EWING, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Antares...
Antares Pharma Announces Appointment of Carmen Volkart to its Board of Directors
28 oct. 2021 08h00 HE
|
Antares Pharma, Inc.
EWING, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced the appointment of Carmen Volkart to its Board...
Antares Pharma Announces Oral Presentation at the 22nd Annual Fall Scientific Meeting of SMSNA
25 oct. 2021 08h30 HE
|
Antares Pharma, Inc.
EWING, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that an abstract on XYOSTED®, a subcutaneous...
Antares Pharma to Report Third Quarter 2021 Financial and Operating Results
21 oct. 2021 08h30 HE
|
Antares Pharma, Inc.
EWING, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its third quarter 2021...
Antares Pharma Enters into Exclusive License Agreement With Lipocine for TLANDO® in U.S.
18 oct. 2021 07h00 HE
|
Antares Pharma, Inc.
EWING, N.J., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that it entered into an exclusive license...
Antares Pharma Initiates Phase I Study For ATRS-1902 For Adrenal Crisis Rescue
30 sept. 2021 09h00 HE
|
Antares Pharma, Inc.
EWING, N.J., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that it has initiated a Phase 1 study for...
Antares Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
08 sept. 2021 08h30 HE
|
Antares Pharma, Inc.
EWING, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief...
Antares Pharma Reports Second Quarter 2021 Financial and Operating Results
05 août 2021 07h00 HE
|
Antares Pharma, Inc.
Increased Revenue 39% Year-Over-Year to $45.0 Million Doubled Net Income to $4.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share EWING, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Antares...
Antares Pharma to Report Second Quarter 2021 Financial and Operating Results
28 juil. 2021 08h30 HE
|
Antares Pharma, Inc.
EWING, N.J., July 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced it will release its second quarter 2021...